ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits ...
Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.
Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback